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An Overview of Orthotopic 
Transplantation of the Liver 
BYERS W. SHAW, JR., M.D., THOMAS E. STARZL, M.D., Ph.D., 
SHUNZABURO IWATSUKI, M.D., 
and ROBERT D. GORDON, M.D. 
The field of liver transplantation has 
undergone a revolution, beginning around 
1980 with the introduction of the immuno-
SUppressant cyclosporine and continuing 
through the next five years. The improved 
survival that has occurred has changed the 
procedure from a rather arduous exercise in 
surgical exotica to a realistic therapeutic al-
ternative for a large number of patients with 
advanced liver disease. Enthusiasm for the 
pr~cedure has spread throughout the world. 
AsIde from the facts that a growing number 
of p~tients are being identified as potential 
reOplents of livers and that the ranks of 
wai.ting candidates continue to expand more 
rapldly than the availability of the procedure, 
!he high profile status of transplant recipients 
In the lay and medical press has infected 
both academic and private institutions with 
the belief that developing programs in liver !h~smlantation will garner new prestige for 
. ~1q hospitals, thus strengthening their po-
SItion in an increasingly competitive battle 
for health care dollars. It is predictable that 
rna~y such programs will come and go rather 
rapIdly. Although a revolution has taken 
Place, offering liver replacement to patients 
is still a complex endeavor. It requires an 
expensive long-term commitment of re-
sources, which the advertising budgets of 
most hospitals cannot support. 
An understanding of the current status of 
hepatic transplantation requires a brief re-
view of the history of the field, a general 
delineation of recipient candidacy require-
ments, a description of the operative tech-
niques for both donor and recipient proce-
dures, and an accounting of results. Mention 
should also be made of the costs of the 
procedure and some estimation of the poten-
tial benefits to society. What the future may 
bring and which research efforts are needed 
are discussed at the end of the chapter. 
HISTORIC NOTES 
The technique of transplanting solid, vas-
cularized organs owes much to the pioneer-
ing efforts of Alexis CarreP and Emerich 
Ullman2 (as does the entire field of vascular 
surgery). These men demonstrated that re-
moving kidneys from one animal and revas-
cularizing them into another not only was 
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possible but also worked so well from a 
technical standpoint that Carrel attributed 
failures to "biological factors" in the host, 
rather than to "surgical factors. "1 
Early Experimental Efforts 
The first reported efforts at hepatic trans-
plantation involved the heterotopic transfer 
of the liver in dogs. These experiments were 
done by Welch,4 and subsequently by oth-
ers, >"7 without the use of immunosuppres-
sion. Despite the fact that in this setting the 
livers were destroyed after several days (most 
likely by rejection), the observation that they 
initially looked normal in color and even 
produced bile supported the technical feasi-
bilityof the proc,edure. 
Orthotopic transplantation of the liver in 
dogs, fIrst reported by Moore and cowork-
ers, 8 at Peter Bent Brigham, and Starzl and 
colleagues/ then at Northwestern Univer-
sity, provided the first test of the methodol-
ogy, since survival of the animals was solely 
dependent upon adequate function of the 
transplanted organs. Once again, these early 
experiments were on unmodified animals. 
The failure rate was exorbitant. Characteris-
tically, Starzl and coworkers persisted in their 
efforts to improve the techniques of surgery 
and anesthesia and the methods of organ 
preservation. In 1960, they were able to re-
port a two-day survival of 22 of 23 unmodi-
fied dogs, with a six-day survival in 19 of 
them. 9 These dogs served as the control 
group for later experiments with immuno-
suppression. These studies demonstrated the 
histopathologic nature of liver rejection and 
eventually proved that rejection could be 
successfully modified with drugs. 10. 11 The 
usefulness of these experiments largely de-
pended upon the development of method-
ology that would eliminate technical errors 
as a cause for failure. Many of these tech-
niques were directly transferable to early 
work in humans and, with only minor mod-
ifications, serve as the foundation for the 
clinical procedure practiced today. 
Although these early experiments without 
immunosuppression helped characterize the 
pattern of rejection of liver grafts, the occa-
sional long-term survival of some of these 
dogs suggested that in contrast to kidney or 
skin grafts (which were uniformly rej 
liver allografts might possess the capaCity 
survive the onslaught of unmodified 
tion. This concept received further support 
when work at other centers showed that pigs 
possessed an even grea ter tendency tOWard 
survival without immunosuppression than 
dogs did. 12 In fact, by 1969 in Cambridge 
England, Caine and associates l3 were able ~ 
demonstrate that these unmodified pigs that 
survived liver grafting were also rendered 
hyporeactive to both skin and kidney grafts 
from the same donor, although full respon. 
siveness to third-party antigens was pre-
servedY Although Starzl's group, working 
with dogs, and, perhaps more important, 
Myburgh's group, working with primates, . 
were unable to demonstrate a similar phe-
nomenon in their experiments, Zimmermann 
and coworkers 15 confirmed the observations 
of CaIne's group using a rat model. 
Working with rats, the Cambridge group 
subsequently showed that the fate of liver 
grafts is highly dependent upon certain im· 
mune response genes of the recipient. They 
classified individuals as either high or low 
responders. The former appear to reject liver 
grafts as readily as they do other organ grafts, 
whereas the latter group not only do not 
reject allograft livers but also gain donor-
specific tolerance. This phenomenon appears 
to involve donor-specific donal deletion. Al-
though they have found no evidence for the 
development of new populations of either 
donor-specific or donor-non-specific sup-
pressor cells, the sera of these rats do contain 
powerful immunosuppressive properties that 
are donor specific. 16 
Although these fmdings are fascinating, 
their direct impact on the clinical situation 
has yet to be realized. Starzl's group and ., 
other early workers realized that the success , 
of clinical liver transplantation would depend 
upon the availability of safe and effective 
regimens of immunosuppression. For the 
most part, these regimens were modeled 
after those fIrst used in earlier experimental 
work with kidney transplants and then tested 
in the canine liver model. One should not 
underestimate the importance of the experi-
mental successes with azathioprinelo. 17. 18 and 
various antilymphocyte preparations (anti-
lymphocyte serum [ALS], antilymphocyte 
globulin [ALG1)l°·I9-22 in paving the way for 
the fIrst clinical trials of liver transplantation. 
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The First Human Trials 
Starzl Jnd Jssociates recorded the (irst at-
tempt at transplantation of the liver in a 
human on March 1, 1963 in Denver, Colo-
.' rado.1.3 Despite an extensive and highly suc-
cessful four-year experience in the laboratory 
working with dogs, Starzl's team failed in 
this iirst clinical effort. The patient, a three-
year-old boy with biliary atresia died on the 
operating table from hemorrhage. During the 
ensuing ten months, four more failures in 
Denver and one each in Boston and Paris 
(Table 18-1) led Starzl to cease further clinical 
trials in Denver for the next three years. Two 
more patients who underwent transplanta-
tion in Denver between the fall of 1966 and 
the spring of 1967 also died. The group then 
succeeded in obtaining extended survival of 
a 1 Vz-year-old girl with primary hepatocel-
lular carcinoma who underwent transplan-
tation on July 23, 1967 and lived for 13 
months before dying from diffuse metas-
tases. 
In May of 1968, under the directior. of 
Professor Roy CaIne, the University of Cam-
bridge Department of Surgery at Adden-
brooke's Hospital in the United Kingdom 
formed a consortium with Dr. Roger Williams 
and the Liver Unit at King's College Hospital 
in London to embark upon a clirlical program 
of liver transplantation. CaIne recently edited 
a book entitled Liver Transplantation that sum-
marizes their experience with 125 patients 
over a 14-year period ending in May 1982.24 
CaIne's experience, in terms of numbers, is 
second only to Starzl's during the first two 
decades of clinical hepatic transplantation, 
and together their two series account for 
more than three fourths of the world's total 
experience. 
A number of other case reF'llrts or small 
series of human liver trJnspl.1I1ts from all 
over the world appeared in the 13 years after 
Starzl's initial step.2,,\ ... .17 For the most part, 
these scattered experiences did not represent 
the long-term institutional commitments that 
would lead to the dev~lopment ot large-scale 
programs. In addition, even at the end of 
1979 a critical analvsis of the overall results 
of even the most" experienced centers did 
little to encourage greater involvement in the 
field. The best one-year survival rate follow-
ing liver grafting was 50% for a group of 30 
patients who were transplanted between 
1976 and 1978. These were Starzl's so-called 
series II patients (Fig. 18-1). Series I consisted 
of 111 patients with a one-year survival rate 
of 29%, and series III consisted of 29 patients, 
of whom 34.5% survived at least one year. 
The overall one-year survival rate in all 170 
patients in series I, II, and ill was 33%. 
Among the first 26 series III patients, only 6 
(23%) survived the first year, leading to the 
publication in 1980 of a paper entitled "De-
cline in Survival Following Liver Transplan-
tation."38 Azathioprine and prednisone 
served as the foundation for immuno-
suppression in these patients. A number also 
received adjuvant therapy with various anti-
lymphocyte preparations.. Cyclophospha-
mide was substituted for azathioprine in the 
treatment of 16 patients in 1971 and 1972, 
and thoracic duct drainage was employed in 
21 patients during 1978 and 1979, but neither 
offered significant improvements in survival. 
During this same interval, CaIne's group had 
a 19% one-year survival rate in their first 93 
patients.38 
Although the techniques of surgery and 
anesthetic management, as well as the meth-
odology for adequate organ preservation, 
Table 18-1. THE FIRST HUMAN TRIALS OF ORTHOTOPIC UVER TRANSPLANTATION 
Survival 
Location Age(Yd Disease (Days) Main Cause of Death 
Denver 3 Extrahepa tic biliary atresia 0 Hemorrhage 
Denver 48 Hepatocellular cancer, cirrhosis 22 Pulmonary emboli, sepsis 
Denver 68 Duct cell carcinoma 7V2 Sepsis, pulmonary emboli, 
Denver 52 Hepatocellular cancer, cirrhosis 
gastrointestinal bleeding 
6% Pulmonary emboli, hepatic failure, 
Boston 58 Metastatic colon carcinoma 
pulmonary edema 
11 Pneumonitis, liver abscesses. hepatic 
failure 
Denver 29 Hepatocellular cancer, cirrhosis 23 Sepsis, bile peritonitis, hepatic failure 
Paris 75 Metastatic colon carcinoma 0 Hemorrhage 
Denver 29 Hepatocellular cancer 7 Hepatic failure. sepsis 
Denver 1 Biliary atresia 10 Hepatic failure. sepsis 
Denver 1% Hepatocellular cancer 400 Carcinomatosis 
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Figure 18-1. Actual survival under azathioprine 
and prednisone. 
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had been fairly well worked out, rejection of 
the liver or infection from immunosuppres-
sion had emerged as the major source of 
mortality. Further improvements in results 
would require improvements in immuno-
suppression. 
The Advent of Cyclosporine 
The early reports of cyclosporine use as an 
immunosuppressanf39-43 ignited a worldwide 
enthusiasm for liver transplantation. Starzl's 
group obtained actuarial one-year survival of 
greater than 70% in the first 67 patients that 
they treated between 1980 and 1982.38• 43 Al-
though patients treated with cyclosporine 
were not separated from groups not so 
treated, CaIne and Williams also reported an 
advantage with the use of cyclosporine. 
Eleven of 18 (60%) patients treated with the 
drug survived between 3 and 31 months.'" 
The real importance of cyclosporine in im-
proving results is diffIcult to assess. The 
argument might be made that other improve-
ments in patient selection, surgical tech-
nique, and patient management have super-
vened to improve the statistical outlook for 
these recipients. More recently, CaIne, in his 
book, noted that excellent results were ob-
tained by both the Hanover and Groningen 
groups even before they began to use cyda-
sporine.24 Yet if one looks at the single largest 
series of patients and examines the results of 
20 years of effort by a single individual, the 
most important factor leading to improved 
patient survival during that era was the in-
. troduction of cyclosporine. The importance 
'I( 
60 
of careful case selection, improvements in 
surgical technique, or better management of 
patient care at some centers cannot be de-
nied. It will become evident throughout this 
chapter that these factors have operated sub-
sequently to effect even further improve-
ments in the Pittsburgh series. 
DONATION AND PROCUREMENT 
OF LIVERS 
Donor Availability 
During 1984 fewer than 300 donor livers . 
were procured and transplanted into human 
recipients in the entire United States. More . 
than half were used by the group at the 
University of Pittsburgh. In 1986 the number 
of liver transplants performed in the United 
States was 924 and by the end of 1987 will 
have risen to over 1000. Liver transplantation 
has been performed at more than 40 centers 
in the United States, and at least seven cen-
ters are now performing over 50 procedures 
annually. 
The prospect that mounting demand for 
liver and other organ transplants will create 
increasing pressure on the medical profes- . 
sion to battle for rare donor organs conjures 
up visions which have heretofore arisen only 
from the imaginations of paperback noveliSts 
and Hollywood screenwriters. The very fact 
that in 1983, a member of the transplant 
community46 proposed a system whidl 
would encourage wholesale buying and seil-
ing of organs, even to the point of compen-
sating unwitting volunteers who might walll 
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o make a few dollars by donating one of 
t eir spare kidneys, suggests that the mate-~al of bestseller lists may not be all that far 
off base. However, the reader should take 
considerable solace from the fact that most 
f the transplant community has publicly ~nsured all suggestions that direct compen-
sation be provided for organ donation. In 
addition, Congress passed legislation in 1984 
(fhe National Transplant Organ Act, P.L. 98-
507) specifically prohibiting commercial sale 
of human organs for transplantation. 
Since suitable organs for transplantation 
have remained relatively scarce, other meth-
ods for increasing their availability must be 
sought..:5 The existing system for organ pro-
curement falls short of optimizing the use of 
available donors. This can best be illustrated 
by an examination of some numbers. 
On the demand side of the equation, The 
American Liver Foundation has estimated 
that, conservatively, approximately 5000 peo-
ple in the United States have liver disease 
which would be optimally treated with liver 
transplantation.-l7 If a best guess mortality of 
50% per year is imposed upon this popula-
tion of patients, then in order for the number 
to remain constant, 2500 new cases of ter-
minal liver disease must develop annually. 
These gross calculations suggest that at fewer 
than 1000 liver transplants in 1987, the cur-
rent system in this country provided the 
option of transplantation to fewer than one 
half of those people who died of liver disease. 
On the supply side, one needs to examine 
two problems which continue to plague the 
system. One is the unavailability of the right 
donor liver at the right time. The other is the 
unavailability of the liver transplant opera-
tion itself. 
The first of these problems is being ad-
dressed by increasing the usage of available 
donors as extra renal organ donors. In 1983, 
more than 3000 cadavers provided kidneys 
for transplantation in the United States, ten 
times the number that provided livers. By 
1986, although the number of cadaveric kid-
ney donations had risen only slightly, the 
number of liver donations had nearly tripled. 
Undoubtedly, new liver transplant centers 
have stimulated more regional interest in 
liver donation, and more of these kidney 
donors have provided livers. However, the 
apprOximately 3000 cadavers from which kid-
neys were obtained represent fewer than 20% 
of the total estimate of 15 to 20,000 victims 
of brain death seen annually in hospit.11s in 
the United States. Minimizing the wastage of 
these donor organs continues to be highly 
dependent upon the efforts of regional trans-
plant and procurement programs to educ<lte 
both the public <lnd the rest of the medical 
community about the increasing needs for 
organs. 
Recent advances in organ preservation 
may allow storage of the liver for up to 24 
hours (unpublished observations, University 
of Wisconsin and University of Pittsburgh). 
In the more distant future, preserving donor 
organs for even longer periods of time, ex-
ceeding days or weeks, will allow true organ 
banking and may do much to correct the 
terrible shortage. This technology is part of 
the ultimate dream in the field of transplan-
tation. Along with the fantasy of fmding the 
"magic bullet" for immunosuppression, it 
gives the surgeon hope for a better future in 
transplantation. 
Donor Selection 
In making the decision about whether to 
use a particular donor liver, the surgeon 
usually must consider a number of variables 
and can seldom rely upon a single set of 
laboratory values or one aspect of the donor's 
history. In addition, the decision must some-
times be tempered by the urgency of the 
proposed recipient's condition. No clear cri-
teria yet exist to reliably predict whether a 
donor liver will provide satisfactory function 
following transplantation. Certain general 
guidelines are useful only in illustrating the 
extremes-those conditions under which 
procurement of a good donor organ is either 
highly unlikely or highly probable. 
Because hypoxia and hypotension seem to 
represent the most serious threats to the 
integrity of the liver, a careful review of the 
donor's history is an essential first step. An 
initial injury requiring prolonged cardiopul-
monary resuscitation or a subsequent course 
complicated by multiple episodes of cardiac 
arrest, hypotensive crises, respiratory failure, 
and hypoxia, or the development of multiple 
organ failure, usually from sepsis, should 
make the transplant surgeon wary. Con-
versely, a stable course in the intensive care 
unit, especially during a prolonged period 
without nutritional support, may not always 
guarantee the quality of the donor liver. 
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Laboratory values are generally much more 
meaningful once the overall history has been 
reviewed. In addition, the more data that 
one can review, the less handicapped one's 
overall assessment will be. Liver function test 
results that appear elevated shortly after an 
injury but subsequently show a marked trend 
toward normal levels offer encouragement, 
especially if the stability of the overall course 
of the donor supports the impression that 
things have improved. In contrast, relatively 
mild but progressive elevation of serum ami-
notransferase (transaminase) levels may in-
dicate continuing hepatic injury, and a search 
of the patient's history may reveal evidence 
of respiratory distress, cardiodynamic insta-
bility, or sepsis. 
The donor surgeon should make the final 
decision about whether a donor liver is ac-
ceptable. This decision is made after visual 
inspection of the donor and the liver at the 
time of recovery. A cyanotic liver (evidence 
of early cirrhosis), marked edema of the liver, 
or the presence of direct hepatic trauma 
should lead to concern about the quality of 
the organ. If the surgeon sees any evidence 
that the overall donor condition has changed 
since the last liver function tests were per-
formed, repeating these tests on an emer-
gency basis may help in the decision of 
whether to offer the liver for transplantation. 
In the end, even the seemingly most pre-
dictable situation may offer surprises. In the 
author's experience with more than 500 liver 
transplant operations between 1981 and 1987, 
the number of times that an apparently per-
fect donor liver has failed to provide ade-
quate function following transplantation is 
matched only by the number of times that a 
so-called poor quality graft, used invariably 
in desperation, has succeeded in saving a 
patient's life. The science of assessing organ 
viability prior to transplantation has failed to 
progress beyond the rather medieval practice 
of sewing it in, releasing the blood flow 
through its vessels, and waiting to see what 
happens. Fortunately, primary failure of a 
liver graft, as discussed later in this chapter, 
has been the least common cause for a second 
transplantation procedure.-IS 
The Donor Procedure 
A detailed description of the techniques of 
liver procurement and multiple organ pro-
curement will not be reiterated here. The 
interested reader should refer to publications 
that outline these principles and provide de-
tailed step by step illustrations of the proce-
dure. 17.49-52 
Liver procurement should not be under-
taken casually. The donor surgeon has the 
responsibility of identifying and preserving 
the arterial blood supply to the graft, avoid-
ing injury to the organ arising from excessive 
manipulation of the liver or improper man-
agement of the donor in the operating room, 
and minimizing warm ischemia by thor-
oughly cooling the hepatic parenchymal 
mass before de arterializing the graft. The 
techniques that have evolved were designed 
to serve these purposes. It should be noted 
that when a donor provides multiple organs 
for transplantation, the quality of individual 
organs has not been jeopardized, as shown 
by several reviews of the authors' experi-
ence.49• 53. 54 Indeed, the need for dialysis in 
the fIrst week following transplantation 
among recipients of kidneys procured in con-
cert with livers or hearts, or with both, has 
been much lower (12-17%) than that re-
ported in other series in which kidneys alone 
were procured. 
Preservation of the Liver 
The inadequacies of the present methods 
of liver preservation are graphically illus-
trated by the urgency still associated with a 
liver procurement exercise. If satisfactory 
preservation of the liver for more than a few 
hours were possible, the spectacle of an al-
ways ready surgical team flying hundreds .of . 
miles in the middle of the night in a Jet 
aircraft, in order to obtain the precious or-
gans would be made archaic. Recipient OJ'" 
erations could then be scheduled somewhat 
more electively, or at least could be started 
after a satisfactory liver was in the hands 
the recipient surgical team. The true value 
12- to 24-hour liver preservation 
possible with the recently develope~ 
servation solution from the UniverSIty 
Wisconsin) goes far beyond the simple 
pediency of converting the transplant 
dure from a night-time to a day-time 
tion. 
From 1981 to 1984, the average cold 
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f 2 to 12 hours. Any ischemic interval longer ~an 6 to 8 hours is cause for concern, al-
though quite satisfactory early function has 
been obtained from a number of organs pre-
served for even longer periods. In the Pitts-
burgh program during those years, the use 
of ischemia times as a predictor of the quality 
of graft function has been nearly impossible 
because of the other variables that influence 
the quality of the liver grafts. 
Minimizing the ischemic interval requires 
starting the recipient procedure before the 
donor team has returned with the new organ. 
The amount of time needed for preparing 
the recipient may also be quite variable, de-
pending upon the diagnosis, a history of 
previous abdominal surgery, or the level of 
skill of the operating surgeon. In most cases, 
the surgeon will prefer not to do anything 
irreversible to the native liver (such as ligat-
ing the artery) until the new liver is in hand. 
Interest in improving hepatic preservation 
has become widespread. Cytoprotection with 
agents such as prostaglandins, 55-58 somato-
statin,59 calcium channel blockers, 60-02 and 
coenzyme Q\063-05 has been one area of focus. 
The use of various osmotic agents, such as 
D20,66 or different oxygen free radical scav-
engers,67. 68 has also begun to show some 
promise in the preservation of different or-
gans in certain animal models. The newly 
developed University of Wisconsin solution 
takes a number of these principles into ac-
METABOLIC ERRORS--44 
BILIARY ATRESIA--
PRIM BIL "'MMMU':U.'--'J:' 
count. The solution contains unique polymer 
sugars (hydroxyethyl starch, lactobionate, 
and raffinose) as non-ionic osmotic agents, 
anti-oxidants, and oxygen free radical scav-
engers (glutathione and allopurinol), and 
both adenosine and phosphate for more 
rapid restoration of adenosine triphosphate 
(A TP) levels following revascularization of 
the liver. This solution follows the earlier 
work by Belzer's group in Wisconsin show-
ing the utility of adenosine and phosphate 
in the preservation of kidneys.09, 70 
The impact of these studies upon clinical 
practice has yet to be determined. Methods 
that offer the prospect of truly long-term 
organ storage for days to weeks, or even 
longer are not yet on the foreseeable horizon. 
Such a leap in preservation technology will 
likely require the kind of revolutionary 
changes that make present day thinking ob-
solete. 
THE RECIPIENT 
Indications for Transplantation 
Figure 18-2 shows the major indications 
for transplantation in a total of 313 patients 
(177 adults and 136 children) who underwent 
transplantation with cyclosporine and pred-
nisone immunosuppression between March 
CIRIRH[lSI:S--70 
ALL PATIENTS 
N = 313 
CIRRHOSIS--57 ~ BILIARY ATRESIA--7 
PRIM BIL Cfooelpfp--P9~~ 
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SCLEROS CHOLANGITIS--29 PRIMARY MALIGNANCY--16 METABOLIC ERRORS--30 
ADULTS CHILDREN 
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Figure 18-2. Indications for liver transplantation in 313 patients from 1980 to 1984. 
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1, 1980 and December 31, 1984. Postnecrotic 
cirrhosis was the most frequent diagnosis in 
adult patients and biliary atresia was most 
frequent among those 18 years or younger. 
Primary biliary cirrhosis and sclerosing cho-
langitis represent two other major diagnostic 
categories in adults. 
Candidacy 
Clear criteria for selecting patients for liver 
transplantation are not yet available (mainly 
because of a lack, until recently, of enough 
patients to provide a valid retrospective anal-
ysis of risk factors). With improvements in 
results, and a situation in which demand far 
outstrips the current availability of the pro-
cedure, optimal selection of recipients has 
become not only justifiable but also manda-
tory. 
Any patient whose life is threatened by 
advanced liver disease or whose lifestyle is 
seriously affected by that disease and for 
whom other medical or surgical therapy of-
fers no reasonable hope for improvement is 
a candidate for liver transplantation. Con-
traindications include the presence of sepsis, 
extrahepatic malignancy, or severe disease of 
other organs that would not be expected to 
improve with liver replacement. The diffi-
culty arises in increasing the criteria for ex-
clusion beyond these simple, rather self-evi-
dent criteria. 
Three Pittsburgh studies indicate what 
some of the risk factors that might obviate 
transplantation are. 
The fIrst was a simple analysis, done in 
mid-1983, of what effect location of the recip-
ient prior to transplantation had on ultimate 
survival. Six-week survival in those who 
went to the operating room from the inten-
sive care unit was 42% compared with 84% 
for those who were in the hospital but on 
the ward and 68% for those who were out-
patient care dependent. 71 
The second was a study of the effect of 
venous bypass on survival of adult patients 
undergoing liver transplantation.72 Overall 
survival at 30 days was found to have been 
improved by the use of venous bypass, but 
these patients appeared to no longer have an 
advantage by 90 days when compared with 
a group of historical controls transplanted 
without the use of venous bypass. The rea-
sons became more evident when these pa-
tients were classified into one of three 
groups, depending upon preoperative risk 
factors. Those in the high-risk group were 
patients who were deeply encephalopathic 
or who had frequent episodes of stage III Or 
IV coma and patients with marked nutritional 
depletion, massive ascites, severe coagulop-
athy, renal failure, or recurrent episodes of 
massive variceal bleeding. Also included 
were patients who were thought to be at 
increased risk because of a history of exten-
sive abdominal surgery involving the liver. 
The use of venous bypass appeared to offer 
the advantage of a greater chance of survival 
to those patients in the low- and medium-
risk groups at both the 30- and 90-day inter-
vals following transplantation. The high-risk 
group, on the other hand, experienced a 
marked improvement in survival at 30 days 
compared with another group of high-risk 
patients transplanted \\;thout venous by-
pass, but they went on to experience an 
inordinate mortality during the next 60 days 
so that by 90 days, their mortality was the 
same as the group without venous bypass. 
In fact, the only long-term survivors in the· 
high-risk, venous bypass group were those 
few patients so classifIed for technical, rather. 
than physiological, reasons. 72 
The third study was a multivariant analysis 
of a variety of patient characteristics in an 
attempt to develop a mathematical formula 
for assigning relative risk scores to patients 
preoperatively. S7 An empirical scoring system 
was created which accounts for the patient's 
preoperative serum bilirubin, prothrombin 
time, amount of ascites, history of 
lopathy, degree of nutrition, renal 
and age. Following transplantation, this 
operative score should be modified by a . 
blood loss factor, which increases the overall 
score if total operative blood loss is excessive. 
The relationship between this empirical ~C?re 
and the probability of the patient SUJ'VlVUlg 
at least six months following liver transpl~ 
tation is best described by a sigmoid shap . 
curve (Fig. 18-3). Depending upon theit 
score, patients could be separated into 
of three major groups: low, inde 
and high risk. The risk for those with 
falling on the steep part of the sigmoid 
were felt to be diffIcult to estimate. iKg~"r>vvD 
of nine patients with high-risk scores (7 
above) only two (22!J'r) survived at least 
months, whereas 79 of 82 (96'70) patients 
low-risk scores (3 or below) were alive at 
months. 
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should not i 
ments have, 
operative su· 
ents, but be\' 
surgery, the 
entirely on ti 
tient. Patient. 
eration for Ii 
tt.'e ravages ( 
Vlval highly i 
attitude Corn 
CUrrent survi· 
Survival CD 
ysis of 313 p. 
dren) with . 
ltIonths are ' 
f;;Vious stud 
% at two y 
that for adui! 
:0 one of· three 
p~eoperative risk 
'-nsk group were 
encephalopathic 
des of stage III Or 
1arked nutritional 
se\'ere coagulop-
rrent episodes of 
. Also included 
hought to be at 
history of exten_ 
'ohing the liver. 
lppeared to offer 
hance of survival 
v- and medium_ 
lOd 90-day inter-
'0. The high-risk 
" experienced a 
~vival at 30 days 
)UP of high-risk 
)u t venous by-
) experience an 
:he next 60 days 
ortality was the 
venous bypass. 
;univors in the 
JUp were those 
echnical, rather 
variant analysis 
eteristies in an 
na tical formula 
)res to patients 
scoring system 
or the patient's 
" prothrombin 
.ry of encepha-
renal failure, 
ation, this pre-
nodified by a 
lses the overall 
,ss is excessive. 
~mpirical score 
:ient surviving 
:ver transplan-
gmoid shaped .. 
g upon their 
-atOO into one 
ndeterminate, 
,e with scores 
;igmoid curve 
lte. However, 
; scores (7 or 
~d at least six 
patients with 
re alive at six 
355 
RELATIONSHIP BETWEEN 6·MONTH SURVIVAL 
AND RISK SCORE 
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figure 16-3. Curve showing theoretical relationship between prospective risk score and an adult patient's probability 
of surviving at least 6 months following liver transplantation. 
The major implication from these studies 
should not be ignored. Technical improve-
ments have done much to improve the peri-
operative survival of liver transplant recipi-
ents, but beyond the immediate interval after 
surgery, the impact of this progress is lost 
entirely on the physiologically high-risk pa-
tient. Patients should be referred for consid-
eration for liver transplantation long before 
the ravages of their liver disease make sur-
vival highly improbable. Justification for this 
attitude comes from an understanding of 
current survival statistics. 
RESULTS 
Survival 
Survival curves based upon life table anal-
ysis of 313 patients (177 adults and 136 chil-
dren) with a minimum follow-up of six 
months are shown in Figure 1~K As in 
previous studies, the survival rate in children 
(77% at two years) is greater (p < .0001) than 
that for adults (59% at two years). The in-
creased mortality in adults occurs mainly 
within the first 90 days after surgery (84% 
9O-day survival in children versus 70.6% in 
adults). One- and two-year survival rates are 
71 and 67%, respectively, for the entire group 
of 313 patients. The actuarial four- and five-
year survival rate is 64.3%, with 37 patients 
at risk at the beginning of the fourth year, 
A further breakdown of these patients into 
diagnostic categories and the resultant sur-
vival curves for adults are shown in Figure 
18-5 and for children in Figure 18-6. At two 
years, adults with sclerosing cholangitis have 
a better chance of survival (p = 0.027) than 
all other adults (71.5% versus 56.8%, respec-
tively). Patients with primary biliary cirrhosis 
also have somewhat better two-year survival 
than all other adults (64% versus 56.6%), but 
the difference is not significant (p = 0.184). 
Adults wtih postnecrotic cirrhosis had a 
55.5% two-year survival rate. The differences 
in survival rates among all diagnostic groups 
are not statistically different at one and two 
years. 
Children, the largest group of patients (72 
with biliary atresia), have a survival curve 
that reaches 78% at one year and remains 
flat thereafter, with four patients at risk at 
the beginning of the futh year. Thirty chil-
dren with metabolic disorders compose the 
second largest group, and they had an 83% 
chance of survival after one year (p = 0.347 
versus the remainder of children), with 25 
children alive and at risk after the first year, 
and 18 children at risk at the start of the 
second year. 
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Figure 18-4. Actuarial survival of 313 liver transplants in 177 adults and 136 children between 1980 and 1984. 
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. A total of 15 patients in the series were 
aged 50 years or older. The one- and two-
year survival rates in this older group were 
.67 and 54.5%, respectively_ The greatest ef-
fect of age upon survival was seen in those 
with cirrhosis (Fig. 18-7). Among the 57 adult 
recipients with cirrhosis, 41 were less than 
40 years of age and 16 were greater than 40 
years. At one year following transplantation, 
survival in the younger group (66%) was 
PERCENT SURVIVAL 
significantly better (p = 0.039) than for the 
older group (50%). The difference was even 
more marked at two years (66 versus 21%, p 
< 0.0001). The seven patients with primary 
biliary cirrhosis aged 51 years or older also 
had a lower two-year survival rate (57%) than 
the 32 patients who were 50 years or younger 
(71.9%), although this difference was not 
significant (p = 0.22). Age was not a factor 
in determining survival in the overall group 
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Figure 1S-7. Actuarial survival after liver transplantation for postnecrotic cirrhosis or primary biliary cirrhosis based 
on age. 
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of adults, using age 40, 45, or 50 years as the 
cutoff point. 
Patients with primary hepatic malignancies 
have one-year survival rates that compare 
quite favorably with the remaining group of 
adults (74% versus 64%, respectively, p = 
0.238). However, at two years, their survival 
decreased significantly (p = 0.015 for one 
versus two years) to 48%, which was worse 
(but p = 0.08) than the remainder of adult 
patients (60.5%). Figure 18-5 reveals this 
eventual rapid decline in survival that occurs 
as the result of tumor recurrence. The issue 
of whether transplantation should be offered 
to these patients and how tumor type might 
affect that decision was the subject of a recent 
report by Iwatsuki,73 which compared trans-
plantation with resection therapy. With rare 
exceptions (e.g., the fibrolamellar type of 
hepatoma), the use of transplantation in the 
treatment of primary hepatic malignancies 
may be justified only when combined with 
experimental protocols employing adjuvant 
therapy in ways that represent a radical de-
parture from current standard approaches. 74 
Quality of Life 
Previously, the authors reported that of 33 
transplant patients of the precyclosporine era 
who survived five years or more following 
transplantation, two subsequently died and 
29 others are managing households, attend-
ing school, or employed full time.7S A look 
at 90 patients treated after the introduction 
of cyclosporine and surviving six months or 
more reveals that all but nine are fully reha-
bilitated. Among the nine exceptions, two 
have recently undergone a second trans-
T-tubc 
1n ..-:" 
cumrnon. . 
c1uct . 
plant, two have required hospitalization for 
treatment of rejection, and five others require 
continuing physical rehabilitation or are re-
ceiving adjuvant tumor therapy. 
IMPROVEMENTS, 1982 TO 1985 
Technical Improvements 
The basic technique of the recipient 
tectomy and the transplantation of the donor 
liver has remained principally unchanged 
(Fig. 18-8). Detailed descriptions are 
able from a number of other sources and 
not be repeated here. 17. 76-78 What will 
covered are the recent changes in 
resulting from the development of the 
nous bypass technique and better "Ialln~I1f:D 
ment of patients by anesthesiologists. 
The technique of venous bypass, 
does not require systemic 
was developed in the laboratory and 
reported by Denmark in 1983,79 and 
modifications for its first clinical use were 
subject of a paper by Griffith and 
(submitted and accepted in mid-1983 but 
fortunately not published until nearly 
years later). The technique was 
routinely in the transplantation of 
patients in Pittsburgh starting in 
1983 (Fig. 18-9). Shaw and associates 
able to report in 1984 that the routine use 
venous bypass resulted in a marked U'-L.l"'''''', 
in mean intraoperative blood loss, an 
proved cardiodynamic stability during 
anhepatic phase, a significant ,rn,nr{1,VPTnt:lI 
in renal function after surgery, and a 
tion in early mortality, including a 
elimination of operative deaths. 72 
a. 
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One must not underestimate, however, the 
of several other factors that undoubt-
improved the overall results during this 
. Not the least of these was the formation 
a liver team by a number of enthusiastic 
11yt::FrfDt:iF"r1y"MlD~ who had an interest in im-
the intraoperative course. The im-
I\I'\ri,,,n('" of monitoring and maintaining ion-
calcium levels and the ability to use the 
to optimize blood prod-
replacement therapy for coagulopathies 
only two results of this interest. 81.82 Dur-
this same interval, the fact that the sur-
team's experience expanded dramati-
also may have had a beneficial effect 
improving results. 
Finally, the more aggressive use of second 
procedures during this time 
to more patients surviving beyond 
first anniversary of their transplant op-
Approximately 20% of a large series 
will require second transplants, 
in the authors' experience, they will 
about a 50% one-year survival rate, 
accounting for about 10% of the overall 
who survive long-term. The best re-
are obtained when the second trans-
m~t is planned on a more or less elective 
basiS, such as following rejection, and the 
results are when it is done on an 
an,p .. ~o ... ,w. basis, such as for primary lack of 
of a new graft or following a tech-
failure such as arterial thrombosis.48 
B(opump 
7mm gott tubmg 
Improvements in 
Immunosuppression 
The most significant change in the man-
agement of immunosuppression in Pitts-
burgh arose from the availability of daily 
cyclosporine blood levels. Evidence quickly 
became overwhelming that absorption and 
metabolism of cyclosporine were highly var-
iable in this group of patients. Absorption 
has been shown to be dependent upon diet, 
and bowel habits and whether the patient 
has diversion of bile through a T tube in the 
bile duct.83-a5 
The regimen of immunosuppression em-
ployed in Pittsburgh in mid-1985 consisted 
initially of the same taper of steroids reported 
previously86 (in adults, 1 g methylpredniso-
lone succinate at the time of transplantation, 
then a taper of 40 mg of steroid/day starting 
at 200 mg and leveling off at 20 mg daily by 
the sixth day, and in children, 500 to 250 mg 
methylprednisolone bolus and a daily taper 
by 20 mg from 100 to 10 mg), combined with 
2 mglkg of intravenous cyclosporine three 
times daily. As soon as the patient's ileus 
had resolved, oral cyclosporine was started 
at 8.75 mglkg twice daily. 
The dose of cyclosporine is adjusted daily 
in order to maintain a trough whole blood 
level of 1000 ng/ml, as measured by radio-
immunoassay. This normally requires an 
initial reduction of the intravenous dose (usu-
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ally by decreasing the frequency of intrave-
nous dosing to twice daily) on about the 
third or fourth postoperative day. If a T tube 
is in place, care should be taken to observe 
cyclosporine blood levels for 24 to 48 hours 
after clamping the tube, since absorption may 
be markedly enhanced. 
In other patients, particularly in children, 
the development of diarrhea usually heralds 
an episode of rejection accompanied by low 
blood cyclosporine levels. In these patients, 
uncertainty exists about whether the diarrhea 
leads to malabsorption of the drug, which 
then leads to low levels and the subsequent 
emergence of rejection, or whether the diar-
rhea may develop as the result of poor bile 
output secondary to liver malfunction, which 
is itself the result of rejection. In the latter 
scenario, an insidious rejection episode may 
serve to amplify itself by causing less bile 
dependent absorption of cyclosporine. 
Interactions with other drugs that may 
alter cyclosporine blood levels must also be 
borne in mind. In the authors' experience, 
phenytoin, barbiturates, and combinations of 
trimethoprim and sulfa antibiotics are the 
drugs most frequently used in liver recipients 
that can markedly lower cyclosporine levels. 
Rejection episodes are treated with an in-
travenous bolus of steroid (usually 1 g meth-
ylprednisolone in adults) followed by a cycle 
of prednisone that is comparable to that 
given over the first six days after surgery. 
More recent additions to the basic immuno-
suppression regimen include the occasional 
use of antithymocyte globulins (ATGAM, 
manufactured by Upjohn and the mono-
clonal globulin, OKT3, manufactured by Or-
tho) or azathioprine in steroid resistant rejec-
tion. Thus far the results with these other 
modalities are too preliminary to be reported, 
but prompt reversal of aggressive, otherwise 
unresponsive rejection has been obtained 
with all three drugs or combinations thereof. 
The fact that rejection remains the most 
prominent cause for failure in liver transplan-
tation only serves to underscore the need for 
continuing to improve the armamentarium 
against it. 
CONCLUSION 
The future of liver transplantation as a 
viable form of therapy for the treatment of a 
variety of liver diseases seems more certain 
than at any time since Starzl's first attempts 
at the operation in the winter of 1963. Per-
forming more than 400 transplant procedures 
on more than 300 patients during a four-year 
period from 1981 through 1984, and without 
the use of any formal process of selection of 
low- or even medium-risk patients, the group 
in Pittsburgh was able to obtain one-year 
survival rates of greater than 70%, with ac-
tuarial five year rates near 65%. The pros-
pects for patients at less risk are even brigh-
ter. 
Since this chapter was written in early 
1985, a number of other centers have begun 
reporting one-year survival rates that range 
from 65% to 85%. These reports represent a 
truly successful diffusion of the technOlogy 
and skills necessary for beginning to address 
the greater need for liver transplant therapy 
that has evolved in this country during the 
past seven years. 
This optimism should not be mistaken 
a license for every curious surgeon or 
tution to dabble in the field. Effective use 
precious donor organs to treat the large 
ber of waiting recipients nationwide rpEIf111rl~1 
full time involvement in the field by 
tions committed not only to providing 
procedure as a service but also to inves,t12:alt-. 
ing new inroads into improving the 
The next five years will likely see the 
gence of 15 to 20 centers . 25 
more transplants per year in the 
States, with at least 10 centers capable 
performing 50 or more operations. 
In the near future, OSllDI,ressiClD, 
will continue to involve the use of CVC:I0Spor, 
ine doses that are more tailored to the 
vidual patient, with the addition of 
agents such as azathioprine or 
preparations of various types, or . 
sporine analogues may prove less toXIC 
replace the current cyclosporine A. The 
cent First International Workshop on . 
entitled II A Potential Breakthrough Ul 
munosuppression," revealed that this 
discovered macrolide, with nO!;UPPI",,! 
sive action very similar to that of 
but at concentrations at least lOO-fold 
may add a significant new weapon to 
polypharmaceutical arma~enKtanurn~ ...... 
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'Slll with cyclosporine, since compara-
~fs low doses of both drugs have tremen-
ti US immunosuppressive effects.1<!I 
dOMuch work is under way, and a great deal 
{ irlterest has been sparked in the field of 
~ patic preservation. As mentioned previ-o~sfvI a numb~r of approaches show promise 
f significant Improvements. Paramount to ~ of this work will be the development of 
some method of accurately assessing graft 
viability prior to the actual transplant. . 
The issue of costs has not been mentIoned 
in this chapter thus far. The mean cost in 
Pittsburgh during fiscal 1983 to 1984 was 
. about 5105,000/case (median costs were 
closer to 575,000). With inflation and an ex-
. ponential increase in the number of cases 
performed there, the costs have no doubt 
risen even more in the last several years. The 
impact upon the national health care system 
, of this new enthusiasm for the procedure 
will not be trivial. However, overall costs of 
liver transplantation therapy will only de-
crease with greater participation in the field 
by a number of centers all striving to improve 
results through better technique, better pa-
tient selection, and better immunosuppres-
sion. 
Finally, one cannot ignore the greater im-
pact that these programs may have upon 
improving health care for an even larger 
portion of society. Advances in the field of 
transplantation undoubtedly will have im-
portant "spin-off" effects upon the ability to 
treat other disorders, such as cancer, autoim-
, mune diseases, and even viral illnesses. 
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